🇺🇸 FDA
Patent

US 8148344

Compositions and methods for mediating RNAi in vivo

granted A61KA61K47/554A61K47/69

Quick answer

US patent 8148344 (Compositions and methods for mediating RNAi in vivo) held by Alnylam Pharmaceuticals, Inc. expires Mon Mar 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Apr 03 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K47/554, A61K47/69, A61P, A61P43/00